Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation. Issue 6 (21st June 2019)

• Record Type: Journal Article
• Authors: Horiuchi, Kohei; Asakura, Takanori; Sakaguchi, Shinji; Saito, Fumitake
• Is Part Of: BMJ case reports. Volume 12:Issue 6(2019)
• Publication Date: 2019-06-21
• Subjects: neurooncology -- spinal cord -- lung cancer (oncology) -- therapeutic indications; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2019-229310
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Intramedullary spinal cord metastases (ISCMs) of non-small cell lung cancer (NSCLC) constitute a serious if infrequent complication, characterised by rapid progression of neurological deficits, with poor prognosis. We describe a 52-year-old man with ISCMs secondary to lung adenocarcinoma who acquired the T790M mutation of the epidermal growth factor receptor (EGFR) after previous use of a first-generation EGFR tyrosine kinase inhibitor (TKI); he was successfully treated with osimertinib. This is the first report of the use of osimertinib in ISCMs: due to its high central nervous system activity, osimertinib could be useful for treating ISCMs secondary to NSCLC in patients who exhibit the T790M mutation.